BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading cause of death worldwide [...]
Main Authors: | Felice Crocetto, Biagio Barone, Vincenzo Francesco Caputo, Matteo Fontana, Ottavio de Cobelli, Matteo Ferro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/5/908 |
Similar Items
-
Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer
by: Matteo Ferro, et al.
Published: (2022-08-01) -
Prostate Cancer: Germline Mutations in BRCA1 and BRCA2
by: Pankaja Umarane, et al.
Published: (2023-03-01) -
Prevalence of Germline <em>BRCA1/2</em> Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis
by: Antonio Cioffi, et al.
Published: (2023-01-01) -
Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
by: Riko Ikeda, et al.
Published: (2024-03-01) -
Germline mutations in 5' to c.7914 of BRCA2 significantly increase risk of prostate cancer
by: Xiao-Hao Ruan, et al.
Published: (2023-01-01)